Evidence map›Paper›PMID 24631682›Full record

ReviewDrug discovery today2014

Cell-based therapies for Huntington's disease.

Yiju Chen, Richard L Carter, In K Cho, Anthony W S Chan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug discovery today, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Drug discovery and development for rare genetic disorders.American journal of medical genetics. Part A · 2017
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yiju ChenDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, 954 Gatewood Rd, NE Atlanta, GA 30329, USA; Department of Human Genetics, Emory University School of Medicine, 615 Michael St, Atlanta, GA 30322, USA.
Richard L CarterDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, 954 Gatewood Rd, NE Atlanta, GA 30329, USA; Department of Human Genetics, Emory University School of Medicine, 615 Michael St, Atlanta, GA 30322, USA; Genetics and Molecular Biology Program, Laney Graduate School, Emory University, 201 Dowman Drive, Atlanta, GA 30322, USA.
In K ChoDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, 954 Gatewood Rd, NE Atlanta, GA 30329, USA; Department of Human Genetics, Emory University School of Medicine, 615 Michael St, Atlanta, GA 30322, USA; Genetics and Molecular Biology Program, Laney Graduate School, Emory University, 201 Dowman Drive, Atlanta, GA 30322, USA.
Anthony W S ChanDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, 954 Gatewood Rd, NE Atlanta, GA 30329, USA; Department of Human Genetics, Emory University School of Medicine, 615 Michael St, Atlanta, GA 30322, USA; Genetics and Molecular Biology Program, Laney Graduate School, Emory University, 201 Dowman Drive, Atlanta, GA 30322, USA. Electronic address: awchan@emory.edu.
Emory National Primate Research CenterEmory University · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Transgenic Huntington's disease monkey resourceR24OD010930 · OD · EMORY UNIVERSITY · PI CHAN, ANTHONY WING SANG · 2012 to 2018
$6.1M
MONITORING STEM CELL GRAFTS USING A NOVEL MRI REPORTERR01NS064991 · NINDS · EMORY UNIVERSITY · PI CHAN, ANTHONY WING SANG · 2009 to 2012
$1.5M
A NOVEL TRANSLATIONAL MODEL OF AUTISUM SPECTRUM DISORDERR21MH100670 · NIMH · EMORY UNIVERSITY · PI CHAN, ANTHONY WING SANG · 2013 to 2014
$491k
A gene and prgenitor cell therapy in Huntington disease miceR21NS084163 · NINDS · EMORY UNIVERSITY · PI CHAN, ANTHONY WING SANG · 2013 to 2014
$427k
NCRR NIH HHS P51RR165NIH HHS OD010930NIH HHS OD P51OD11132NIH HHS P51 OD011132NIH HHS R24 OD010930NIMH NIH HHS MH100670NIMH NIH HHS R21 MH100670NINDS NIH HHS NS064991NINDS NIH HHS NS084163NINDS NIH HHS R01 NS064991NINDS NIH HHS R21 NS084163
6 · The paper itself

Abstract

Cell-based therapies are a viable option for the long-term treatment of Huntington's disease (HD), which is characterized by progressive neurodegeneration predominately in the striatum and cortex. Current research focuses on genetic suppression of the mutant huntingtin (mHTT) gene and cell replacement therapy of the lost cells in HD. As we discuss here, the recent development of induced pluripotent stem (iPS) cells technology demonstrated the potential of cell-based therapy in rodent models. It was shown that iPSCs were capable of differentiating into lost neurons in HD and stem cell grafts can improve motor deficiency in HD rodent models. Altogether, these findings have shown great promise for developing the foundation of the cell-based therapy.

Indexed as

AnimalsCell- and Tissue-Based TherapyGenetic TherapyHumansHuntingtin ProteinHuntington DiseaseInduced Pluripotent Stem CellsNerve Tissue ProteinsHTT protein, humanHuntingtin ProteinNerve Tissue Proteins

Identifiers

PMID24631682
PMCPMC4082729
OpenAlexW1981471255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.